Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders TORONTO, ONTARIO

Zentaris Announces Results of Virtual 2023 Meeting of Shareholders

ONTARIO, June 14, 2023 - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"),

a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,

today announced that all items of business were approved at its Virtual Annual General and Special Meeting of Shareholders (the "AGM")

the AGM, all items of business were approved. The individuals noted below were elected as directors of the Company:

the AGM, Deloitte LLP was appointed as the Company's auditor.

Company is an "Eligible Interlisted Issuer" as such term is defined in the TSX Company Manual. As an Eligible Interlisted

Issuer, the Company has relied on an exemption pursuant to Section 602.1 of the TSX Company Manual from Section 613 of the TSX Company

Manual, the effect of which is that, subject to the satisfaction of certain conditions prescribed by the Toronto Stock Exchange, the

Company will not have to comply with certain Canadian requirements in connection with the Company's long-term incentive plan. As

a result, shareholders were not asked to approve the unallocated entitlements under the Company's long-term incentive plan at the

full voting details, please see the report of voting results filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.

Aeterna Zentaris Inc.

Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic

products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen ;

Ghryvelin ), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth

hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it

for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

Zentaris is dedicated to the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially

address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's

disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).

more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

press release contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation

and regulations and such statements are made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995.

Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates,"

"believes," "intends," "potential," "possible," and similar expressions. Such statements,

based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and

unknown, many of which are beyond our control.

statements in this press release include statements regarding the holding of, attending, and voting before and at, the AGM. Forward-looking

statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements

stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking

information. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional

information on risks and uncertainties, including those risks discussed in our Annual Report on Form 20-F and annual information form,

under the caption "Risk Factors". Given the uncertainties and risk factors, readers are cautioned not to place undue reliance

on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any

of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental

authority or applicable law.

securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts

no responsibility for the adequacy or accuracy of this release.

T: +1 (833) 475-8247